AI Takes the Lab Loop, Borders Tighten, and Vendor Software Rewrites R&D Workflows

By DripPublished

The gist

This week R&D shifted from using AI as a search layer to letting it steer experiments, workflows, and compliance gates directly.

This week’s developments

Pfizer Puts Kosmos AI into Oncology, Immunology, and Internal Medicine Workflows

Pfizer’s October 29, 2026 deployment of Kosmos AI with Edison Scientific across oncology, immunology, and internal medicine marks the next step in the shift from platform integration to AI-mediated execution. Pfizer said the platform will combine public literature with proprietary drug-development data and support work from target identification through clinical development and regulatory filing.

The disclosed performance signals are meaningful even if they are not Pfizer-specific: one evaluation reviewed about 1,500 papers, executed roughly 42,000 lines of code, and reached 79.4% statement accuracy, with reproducibility of 85.5% for data analysis, 82.1% for literature review, and 57.9% for synthesis. Edison has also reported a 4.2-hour draft of a nonclinical regulatory section versus about 100 expert hours, plus 98% detection of planted source-data errors.

The practical shift is now less about connecting systems and more about governing how work is executed inside them. For scientists and R&D managers, the advantage will increasingly come from validation discipline, provenance checks, and exception handling layered onto the workflows already taking shape, not from domain expertise alone.

How should we adapt workflows and governance for AI-driven drug development?

If you're an individual contributor

  • AI will draft more of your science; your edge is catching what it misses.
  • Get strong at provenance checks, error spotting, and synthesis review—those skills will protect your role as routine analysis gets automated.

Sources

If you manage a team

  • Your team’s value shifts from producing work to validating AI-driven work.
  • Coach scientists on review discipline and exception handling; reallocate time from manual drafting to oversight, QA, and judgment calls.

Sources

If you lead the organization

  • The bottleneck is moving from execution speed to governance quality.
  • Invest in AI operating rules, validation layers, and talent that can supervise models; redesign workflows before AI errors scale.

Sources

Google and Roche Put a Co-Scientist Workflow at the Center of Drug Design

Google and Roche advanced a unified discovery platform built around an AI-enabled “co-scientist” workflow that links target and biology discovery, candidate generation, experimental validation, and model refinement. DeepMind extended Antigravity’s drug-discovery stack with new Cheminformatics Skills in its Science plug-in, adding literature and patent search, compound curation, matched molecular-pair analysis, potency modeling, and molecule proposal with synthesis routes. DeepMind also demonstrated the workflow on crizotinib and lorlatinib analogs, using thousands of compounds to propose novel rigidified macrocycles in about an hour.

The combined message is clear: after the move to AI operating layers and then supervised closed-loop R&D, discovery platforms are now pushing that loop deeper into day-to-day medicinal chemistry and target work. The emphasis is shifting from coordinating separate tools to running a single environment where search, design, and experimental feedback stay continuously connected.

For scientists and R&D teams, the practical shift is less about replacing expertise than compressing iteration time. The work now moves toward defining better prompts, curating cleaner data, and deciding faster which AI-generated candidates deserve synthesis and testing.

How should we redesign discovery workflows around AI co-scientists?

If you're an individual contributor

  • Your edge shifts from bench work to judging AI-designed candidates fast.
  • Get sharper at prompt design, data curation, and triaging AI hits for synthesis—your value is in better calls, not more manual cycles.

If you manage a team

  • Your team’s bottleneck is now judgment, not tool access.
  • Coach scientists on AI review, exception handling, and closed-loop iteration; reallocate time from routine search to candidate selection.

Sources

If you lead the organization

  • Your discovery model must move from tools to an AI-run operating loop.
  • Invest in unified platforms, cleaner data, and AI-literate talent; redesign R&D around faster design-test-learn cycles before rivals do.

Sources

Taiwan, Vietnam, and China Add New Friction to Cross-Border R&D Flows

Taiwan, Vietnam, and China each added new layers of review this week that can slow cross-border R&D inputs and collaboration, but the pattern still looks like heavier compliance rather than a full shift to execution control. Taiwan’s November 2026 export-control proposals would expand restrictions on advanced semiconductor technologies, including advanced AI chips, AI servers with controlled processors, and key wafer-fabrication materials and parts, while also strengthening end-use and anti-circumvention rules for shipments ultimately destined for China.

Vietnam is moving toward stricter cross-border data governance under Decree 13/2023 and newer rules effective 1 January 2026, under which transfers of important or core data abroad may require formal impact assessments or prior approval. China has implemented outbound-investment security reviews under State Council Order No. 837 and is proposing tighter limits on exports of advanced AI technologies and related transfers.

For R&D teams, this is the next layer of friction on top of the infrastructure and perimeter controls already in view: semiconductor supply chains, cloud-based experimentation, offshore data storage, and overseas AI investment now face longer approval cycles, more documentation, and more scrutiny on where data, models, and hardware move next.

How should we adapt R&D workflows and approvals now?

If you're an individual contributor

  • Cross-border R&D work is slower now; your edge is navigating the friction.
  • Get sharper on export, data, and AI transfer rules—people who can keep work moving without tripping reviews will stand out.

Sources

If you manage a team

  • Your team’s bottleneck is shifting from execution to approvals and evidence.
  • Coach for documentation discipline, review-ready handoffs, and escalation judgment; speed now comes from fewer compliance surprises.

If you lead the organization

  • Your R&D operating model now needs compliance built in, not bolted on.
  • Reassess where data, models, and hardware sit; fund governance and regional design now, or approvals will start dictating strategy.

SCIEX and Waters Push LC–MS Workflows Further Into Vendor-Controlled Software

SCIEX launched LeadScape 4.0 and Waters announced its November 3, 2026 acquisition of MOBILion Systems, two moves that show R&D vendors competing on software-controlled workflows rather than instrument specs alone. LeadScape 4.0 automatically generates LC–MS/MS methods from existing DiscoveryQuant MRM parameters, then runs batch creation, data acquisition, processing, reporting, and review inside SCIEX OS. SCIEX says the system can process a 384-well plate in 11 minutes versus 160 minutes in conventional workflows.

Waters is adding MOBILion’s SLIM ion-mobility technology and engineering team to its AI-enabled proteomics strategy, giving it a faster separation layer for proteomics applications. The common direction is clear: less manual workflow assembly, more standardized automation from method setup through data output.

For R&D teams, this extends the shift from stitching together steps to managing vendor-defined pipelines. The near-term payoff is faster turnaround, fewer manual handoffs, and more consistent outputs for review and decision-making. Teams that can adapt quickly will spend less time on routine execution and more time interpreting results, validating methods, and choosing the right platform stack.

How should we adapt workflows and skills for automated LC-MS software?

If you're an individual contributor

  • Manual LC–MS setup is shrinking; method judgment is your edge now.
  • Learn vendor workflows fast and get better at reviewing outputs, exceptions, and method fit — that's what keeps you valuable.

If you manage a team

  • Your team's value is moving from running assays to supervising automation.
  • Shift coaching toward method validation, exception handling, and software fluency so the team can trust vendor-built pipelines.

If you lead the organization

  • You now compete on workflow control, not just instrument performance.
  • Rework hiring and platform strategy around software-led automation, data review, and vendor lock-in risk before the stack hardens.

Sources

Uncertainty Now Drives the Next Experiment in R&D Workflows

In LC method development, the next run is now being chosen by predictive uncertainty, not just expected chromatographic performance. In an in-silico test of 122 randomized mixtures, that uncertainty-driven rule missed peak tracking only once at the required 0.5 resolution, versus about a 14% failure rate for conventional chromatographic-response-function optimization. Related lab results reinforce the same reliability shift: ML models detected developing flow-path clogs earlier from pressure trends, and ensemble ML on difficult protein chromatograms cut peak-integration start/stop variability by 2–3x versus commercial CDS automation.

This is the next control loop after simulation-first validation and virtual commissioning: the model’s confidence determines where to spend the next experiment, concentrating effort in poorly known retention and peak-tracking regions before failure shows up in the lab. The same logic is spreading across simulation-heavy R&D, from patient-specific biomedical decision tools to energy workflows built around VASP, Quantum ESPRESSO, STAR-CCM+, EnergyPlus, and Modelica.

For practitioners, the progression is practical: don’t just ask whether a model predicts well. Ask where it is uncertain, how that uncertainty is surfaced, and whether your next experiment or simulation is being chosen to reduce risk, not just improve fit.

How should we operationalize uncertainty-driven decisions across our R&D workflow?

If you're an individual contributor

  • Your edge shifts from running experiments to steering uncertainty.
  • Learn to read model confidence and choose the next run that reduces risk, not just boosts fit.

If you manage a team

  • Your team must coach models, not just execute them.
  • Train people to spot uncertainty, exception cases, and failure signals so experiments target the riskiest gaps.

Sources

If you lead the organization

  • Your R&D model is now judged by risk reduction, not prediction alone.
  • Invest in uncertainty-aware workflows and talent that can manage model-driven experiment selection before competitors do.

Part of these trends

Stay ahead in Research & Development (R&D)

Get the weekly Research & Development (R&D) brief in your inbox — the developments, what they mean by seniority, and what to do next.